Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in moderate and severe atopic dermatitis (Extension of ZGJAK025)
NCT05676242Phase 3Completed
- Sponsor
- Zelgen
- Start
- Jan 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of jaktinib in atopic dermatitis (AD) (3 arms), sponsored by Zelgen. Primary endpoints: Treatment Emergent Adverse Event at 36 weeks and Serious Adverse Event at 36 weeks. Started Jan 2023; status: completed.
02
Drugs
jaktinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05676242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676242.